A
IRON icon

AJOVista’s Disc Medicine IRON Stock Holding History

AJOVista’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,091
Closed -$63K – 233
2023
Q4 		$63K Buy
+1,091
New +$55.9K 0.08% 254

Other funds holding IRON

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AJOVista's IRON Position: Q1 2024 in Review

AJOVista sold out of Disc Medicine (IRON) in Q1 2024, closing a stake of 1,091 shares — an estimated $63K sold.

AJOVista first reported a position in IRON in Q4 2023 and held it in 1 quarter. The position peaked at $63K in Q4 2023. 130 funds tracked by Wall St. Rank hold IRON as of Q1 2024.

  • AJOVista reported no remaining Disc Medicine position as of Q1 2024 after selling out during the quarter.
  • AJOVista sold 1,091 Disc Medicine shares in Q1 2024, an estimated $63K.
  • AJOVista first reported a position in Disc Medicine in Q4 2023 and held it in 1 quarter.
  • AJOVista's Disc Medicine position peaked at $63K in Q4 2023.
  • 130 funds tracked by Wall St. Rank held Disc Medicine as of Q1 2024.

Based on AJOVista's 13F filing for Q1 2024, filed 10 May 2024.